A new mechanism of methotrexate action revealed by target screening with affinity beads

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1832-1839

  Uga, Hitoshi ^a   Kuramori, Chikanori ^b   Ohta, Akiko ^a   Tsuboi, Yasunori ^a   Tanaka, Hiroshi ^b   Hatakeyama, Mamoru ^b   Yamaguchi, Yuki ^b   Takahashi, Takashi ^b   Kizaki, Masahiro ^c   Handa, Hiroshi ^b  

^a Aphoenix Inc   (Japan)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYTARABINE; DEOXYCYTIDINE KINASE; DIHYDROFOLATE REDUCTASE; METHOTREXATE; NUCLEOTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CELL DEATH; CHROMATOGRAPHY, AFFINITY; CHROMOSOMES, HUMAN; DEOXYCYTIDINE KINASE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; JURKAT CELLS; METHOTREXATE; MICROSPHERES; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 33751160861     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.025866     Document Type: Article

References (40)

1. Alarcon GS (2000) Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology 47:259-271.
2. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, and Jolivet J (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726.
3. Anguera MC, Field MS, Perry C, Ghandour H, Chiang EP, Selhub J, Shane B, and Stover PJ (2006) Regulation of folate-mediated one-carbon metabolism by 10-formyltetrahydrofolate dehydrogenase. J Biol Chem 281:18335-18342.
4. Arner ES and Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67:155-186.
5. Austin CP, Brady LS, Insel TR, and Collins FS (2004) NIH Molecular Libraries Initiative. Science (Wash DC) 306:1138-1139.
6. Azuma A, Huang P, Matsuda A, and Plunkett W (2001) Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol 61:1497-1507.
7. Bohman C and Eriksson S (1988) Deoxycytidine kinase from human leukemic spleen: preparation and characteristics of homogeneous enzyme. Biochemistry 27:4258-4265.
8. Bolin JT, Filman DJ, Matthews DA, Hamlin RC, and Kraut J (1982) Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J Biol Chem 257:13650-13662.
9. Bolli R, Nalecz KA, and Azzi A (1985) The aggregation state of bovine heart cytochrome c oxidase and its kinetics in monomeric and dimeric form. Arch Biochem Biophys 240:102-116.
10. Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH, and Mitchell BS (1991) Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88:1531-1535.
11. Datta NS, Shewach DS, Hurley MC, Mitchell BS, and Fox IH (1989) Human Tlymphoblast deoxycytidine kinase: purification and properties. Biochemistry 28:114-123.
12. Drews J (2000) Drug discovery: a historical perspective. Science (Wash DC) 287:1960-1964.
13. Edelstein M, Vietti T, and Valeriote F (1975) The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. Cancer Res 35:1555-1558.
14. Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, Brady L, Browne LJ, Calvin JT, Day GJ, et al. (2005) Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119:219-244.
15. Genestier L, Paillot R, Quemeneur L, Izeradjene K, and Revillard JP (2000) Mechanisms of action of methotrexate. Immunopharmacology 47:247-257.
16. Godsey MH, Ort S, Sabini E, Konrad M, and Lavie A (2006) Structural basis for the preference of UTP over ATP in human deoxycytidine kinase: illuminating the role of main-chain reorganization. Biochemistry 45:452-461.
17. Hiramoto M, Shimizu N, Nishi T, Shima D, Aizawa S, Tanaka H, Hatakeyama M, Kawaguchi H, and Handa H (2002) High-performance affinity beads for identifying anti-NF-kappa B drug receptors. Methods Enzymol 353:81-88.
18. Hughes TL, Hahn TM, Reynolds KK, and Shewach DS (1997) Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry 36:7540-7547.
19. Kakihara T, Fukuda T, Tanaka A, Emura I, Kishi K, Asami K, and Uchiyama M (1998) Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma 31:405-409.
20. Kawaguchi H, Asai A, Ohtsuka Y, Watanabe H, Wada T, and Handa H (1989) Purification of DNA-binding transcription factors by their selective adsorption on the affinity latex particles. Nucleic Acids Res 17:6229-6240.
21. Keszler G, Spasokoukotskaja T, Csapo Z, Talianidis I, Eriksson S, Staub M, and Sasvari Szekely M (2004) Activation of deoxycytidine kinase in lymphocytes is calcium dependent and involves a conformational change detectable by native immunostaining. Biochem Pharmacol 67:947-955.
22. Krawiec K, Kierdaszuk B, Eriksson S, Munch Petersen B, and Shugar D (1995) Nucleoside triphosphate donors for nucleoside kinases: donor properties of UTP with human deoxycytidine kinase. Biochem Biophys Res Commun 216:42-48.
23. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, and Peterson BA (2001) Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 19:4014-4022.
24. Muus P, Drenthe Schonk A, Haanen C, Wessels H, and Linssen P (1987) In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk Res 11:319-325.
25. Nishi T, Shimizu N, Hiramoto M, Sato I, Yamaguchi Y, Hasegawa M, Aizawa S, Tanaka H, Kataoka K, Watanabe H, et al. (2002) Spatial redox regulation of a critical cysteine residue of NF-κB in vivo. J Biol Chem 277:44548-44556.
26. Owens JK, Shewach DS, Ullman B, and Mitchell BS (1992) Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52:2389-2393.
27. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, and Keating MJ (1987) Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005-3011.
28. Roberts D, Peck C, Hilliard S, and Wingo W (1979) Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells. Cancer Res 39:4048-4054.
29. Sabini E, Ort S, Monnerjahn C, Konrad M, and Lavie A (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10:513-519.
30. Shewach DS, Reynolds KK, and Hertel L (1992) Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42:518-524.
31. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, et al. (2000) High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18:877-881.
32. Smal C, Cardoen S, Bertrand L, Delacauw A, Ferrant A, Berghe GV, Neste EV, and Bontemps F (2004) Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem Pharmacol 68:95-103.
33. Smal C, Vertommen D, Bertrand L, Ntamashimikiro S, Rider MH, Van Den Neste E, and Bontemps F (2006) Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 281:4887-4893.
34. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, et al. (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461-2470.
35. Usova EV and Eriksson S (1997) The effects of high salt concentrations on the regulation of the substrate specificity of human recombinant deoxycytidine kinase. Eur J Biochem 248:762-766.
36. Wada T, Watanabe H, Kawaguchi H, and Handa H (1995) DNA affinity chromatography. Methods Enzymol 254:595-604.
37. Wang LM and Kucera GL (1994) Deoxycytidine kinase is phosphorylated in vitro by protein kinase C alpha. Biochim Biophys Acta 1224:161-167.
38. Webb TR (2005) Current directions in the evolution of compound libraries. Curr Opin Drug Discov Dev 8:303-308.
39. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, and Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822.
40. White JC and Capizzi RL (1991) A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. Cancer Res 51:2559-2565.